AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02622412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-professional breathlessness service (MBS)
Description: Patients visit the MBS twice. At week 1, delivered by palliative care specialists and respiratory disease specialists, patients receive an detailed assessment of breathlessness, relevant symptoms beyond breathlessness, psychosocial issues and carer burden. Recommendations are provided, and reviewed at the concluding visit in week 6 with palliative care specialists. In between these visits, weekly physiotherapy sessions focus on positioning, breathing techniques, exercise as well as pacing and fatigue management. Further support from the multi-professional expert team is given as needed.
Study NCT02622412 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delayed MBS Intervention
Description: Patients will wait 8 weeks for start of intervention and will receive standard care in the meantime with access to respiratory medicine, general practitioners and palliative care services as needed. Standard care includes support by their general practitioners and disease orientated treatment (e.g. anti-obstructive treatment, oxygen supply if indicated, chemotherapy).
Study NCT01744379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Study NCT04177264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occipito-Atlantal Decompression (OA DC)
Description: The participant lies supine in a relaxed state while the investigator cradles the patient's head with their hands, middle finger pads along the inferior aspect of inion, reaching to the occipito-atlantal joint. The investigator then applies gentle posterior and cephalad traction to the occiput, while bringing the elbows together. This results in supination of the hands and separation of the middle fingers, creating a posterior-lateral force vector to either side of the foramen magnum. The pressure is maintained until softening of the underlying structures is felt. The procedure is applied for 10 minutes.
Study NCT04177264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Occipito-Atlantal Decompression (Sham OA DC)
Description: The participant lies supine in a relaxed state while the investigator applies light touch to the patient's head with their hands.
Study NCT04177264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Splenic Lymphatic Pump Technique (SpLPT)
Description: With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigatory compresses and releases the spleen at a rate of 20 compressions/min for 3 min.
Study NCT01744379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03879525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMR-based-interventional method
Description: Questionnaire delivery method. Participants will complete standard care anxiety and depression screening and quality of life assessment directly into the patient entered section of the EMR, administered on arrival in the clinic.
Study NCT03879525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-based-standard method
Description: Questionnaires delivered via phone. Participants will complete standard care anxiety and depression screening and quality of life assessment via phone. Standard delivery method.
Study NCT02073448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK530G
Study NCT02799472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Capsule, tablet or liquid administered orally or as SC injection.
Study NCT02799472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic (or folinic) acid
Description: Capsule, tablet or liquid and will be administered orally.
Study NCT02799472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic (or folinic) acid
Description: Capsule, tablet or liquid and will be administered orally.
Study NCT04302376 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cather-related thrombosis ultrasonography
Description: Doppler and compression ultrasound to detect catheter-related thrombosis
Study NCT04067401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wingman Connect
Description: Wingman-Connect combines group and individual skill training. Group exercises build cohesion, belonging and shared purpose, and promote value of healthy unit, giving and receiving support. Individual skills promote the ability to thrive during transitions, manage stressors and meet career goals, and decrease barriers to utilizing organizational resources (family, health). The training has a total of 22 modules comprised of specific learning objectives and activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
Study NCT04067401 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: Stress management training reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
Study NCT01815528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Description: Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:~1. 10 µg on day 0~2. 20 µg on day 3~3. 50 µg on day 7~4. 150 µg on day 10
Study NCT01515462 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OTL-103
Description: OTL-103 is an autologous CD34+ cells collected from bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding Wiskott-Aldrich syndrome (WAS) protein
Study NCT01547026 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Intentions
Description: In a 10 minute structured therapy session patients are assisted to build up implementation intentions to participate in the sports program.
Study NCT01905930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCM Cervical Disc
Description: Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
Study NCT01905930 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion (ACDF)
Description: Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
Study NCT00873236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00873236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alpha-2a
Description: Given SC
Study NCT03569696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: The treatment phase will begin 10 ± 2 weeks from completion of R- anthracycline based therapy. Cycle 1 day 1 will occur within 72 hours from enrolment. Study treatment will be continued until nivolumab discontinuation due to disease progression, unacceptable toxicity or completion of 2 years or 30 doses of therapy. Study drug nivolumab will be administered intravenously every 2 weeks as described in the investigator brochure (IB) in a dose of 240mg over 30 minutes 46 for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
Study NCT03035305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid-based Nutrient Supplement (LNS)
Description: For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: 15 sachets/month or 50g every two days for 4 weeks~* For children aged 12-59 months: 21 sachets/month or 50g per day for 3 weeks
Study NCT03035305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention
Description: For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg~* For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg~D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine
Study NCT03035305 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Seasonal malaria chemoprevention
Description: For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg~* For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg~D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine
Study NCT02893306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Description: origin: bone marrow of healthy donor; manipulation: ex vivo expanded; via: intravenous; vehicle: 5% human recombinant albumin in physiological serum; dose: 2-3 millions/Kg; dosage: single
Study NCT00643123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 300-600 mg/day over a 6 week period
Study NCT00643123 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance
Study NCT02922894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute episodic hypoxia
Description: The subjects will undergo 30 minutes of baseline monitoring followed by 15 episodes of one minute of episodic hypoxia with supplemental CO2 to maintain isocapnia. This is followed by a 45 minute recovery period.
Study NCT02922894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Description: Supplemental oxygen therapy for 6 weeks
Study NCT02922894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: 100mg before bedtime
Study NCT02922894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One placebo pill before-bedtime
Study NCT02922894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Room air will be administered instead of episodic hypoxia or supplemental oxygen..
Study NCT04116749 — intervention group
Intervention type: OTHER
Intervention: Water
Description: Drink water freely until 2 hours before anesthesia.
Study NCT01417052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg LX3305 QD
Description: 50 mg LX3305 once daily in capsule form
Study NCT01417052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg LX3305 QD
Description: 100 mg LX3305 once daily in capsule form
Study NCT01417052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg LX3305 QD
Description: 150 mg LX3305 once daily in capsule form
Study NCT01417052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg LX3305 QD
Description: 200 mg LX3305 once daily in capsule form
Study NCT01417052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg LX3305 QD
Description: 250 mg LX3305 once daily in capsule form
Study NCT01417052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg LX3305 QD
Description: 300 mg LX3305 once daily in capsule form
Study NCT01417052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg LX3305 QD
Description: 400 mg LX3305 once daily in capsule form
Study NCT01417052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg LX3305 BID
Description: 250 mg LX3305 twice daily in capsule form
Study NCT01417052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg LX3305 QD
Description: 500 mg LX3305 once daily in capsule form
Study NCT01417052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo dosing in capsule form
Study NCT04177264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Splenic Lymphatic Pump Technique (Sham SpLPT)
Description: With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigator will maintain light touch at these positions for 3 minutes. No compressions are performed.
Study NCT04177264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Description: A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 10 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.
Study NCT04177264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS)
Description: A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
Study NCT02015091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: The PfSPZ Vaccine is composed of radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) and is designed to prevent malaria in adults, children, and infants. It is formulated in phosphate buffered saline (PBS) with 1% human serum albumin (HSA). Sanaria Incorporated (Sanaria), Rockville, Maryland, developed and produced the PfSPZ Vaccine.
Study NCT01352650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plerixafor
Description: Cohort 1 will receive plerixafor at a dose of 320 mcg/kg, cohort 2 will receive plerixafor at a dose of 540 mcg/kg and cohort 3 will receive plerixafor at a dose of 810 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.
Study NCT01352650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine
Description: decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles
Study NCT02267057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol granulate supplied by Weifa (Paracet) and 1 g paracetamol tablets produced by Kragerø tablettproduksjon for blinding purposes.
Study NCT03748511 — intervention group
Intervention type: OTHER
Intervention: fibroscan and stool sample
Description: patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
Study NCT02267057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine 5 micrograms/hour and 10 micrograms/hour transdermal system produced by Mundipharma, identical to placebo transdermal system.
Study NCT02150200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shorter hospitalization stay
Study NCT02150200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnaires
Study NCT02150200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Study NCT02073448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD0271
Study NCT01438788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low protein diet
Description: Patients will receive a diet with 0.6-0.8 grams of protein/kilogram body weight/day for one year. Bread, biscuits and pasta will be in part substituted with aproteic food.
Study NCT01386996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol Easyhaler 320/9 microg
Description: 2 inhalations as a single dose
Study NCT02073448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD1579
Study NCT00936754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brown seaweed powder
Description: 500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
Study NCT02267057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol placebo
Description: Paracetamol placebo tablets produced by Kragerø tablettproduksjon.
Study NCT02267057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buprenorphine placebo
Description: Buprenorphine transdermal system placebo produced by Mundipharma.
Study NCT01813461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled prodrug isavuconazonium sulfate
Description: oral
Study NCT00759148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%
Description: Eye drops
Study NCT01386996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler forte
Description: 2 inhalations as a single dose
Study NCT00759148 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin AF Vehicle
Description: Inactive ingredients used as a placebo for masking purposes
Study NCT00861783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan and ON 01910.Na
Description: ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Irinotecan 180 mg/m2 will initially be administered by IV infusion over 90 minutes q2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labelling.
Study NCT00861783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin and ON 01910.Na
Description: ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Oxaliplatin 85 mg/m2 will initially be administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labeling.
Study NCT02137083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2 D2 every 21 days
Study NCT02137083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 D2 every 21 days
Study NCT02137083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg D1, D15, D29, D57, every 28 days later
Study NCT03182257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7579
Description: ONO-7579 Tablets
Study NCT03819725 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Glucose monitoring
Description: FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla®) . Interstitial glucose measurements will be recorded during 2-5 days and during meals.
Study NCT01824615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 37.5mg everyday from D1-D28
Study NCT00723099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo umbilical cord blood transplant
Study NCT00723099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04247490 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: pediatric AIH
Description: pediatric patients with clinical, laboratory (transaminase and IgG increase), instrumental (ultrasound, liver biopsy) characteristics
Study NCT01751412 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Study NCT02079792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lying Head Back Position
Description: Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort.
Study NCT02079792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head Down and Forward Position
Description: Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards.
Study NCT04110028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Nicotinamide riboside in different doses
Study NCT00723099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV
Study NCT00723099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00723099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00723099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO